Профессор, доктор медицинских наук Тобиас Кек
Medicine

Precision therapy of patients with psoriasis – Zhukov – Herald of dermatology and venereology

- March 28, 2022 | April 22, 2022 - Kate

Precision Therapy for Psoriasis Patients

Precision therapy of patients with psoriasis

Cover

In this review, the systematization of information was carried out in a new direction – precision medicine in the aspect of the study of psoriasis. An idea of ​​the relevance, basic concepts is given, a modern classification of biomarkers is given. Examples of each type of biomarker are presented, their role in the diagnosis and treatment of patients. The relationship of the personalized and precision approach to patient management is indicated. The main directions of development of this section of medicine are indicated.

Keywords

About authors

A. S. Zhukov

The author responsible for correspondence.
Email: [email protected].
Ph.D., doctoral student of the Department of Skin and Venereal Diseases

194044, Russian Federation, St. Petersburg, ul. Academician Lebedeva, 6 Russia

V. R. Heiruddinov

Email: [email protected].
D.M., Associate Professor, Associate Professor of the Department of Skin and Venereal Diseases

194044, Russian Federation, St. Petersburg, ul. Academician Lebedeva, 6

A. V. Samtsov

Email: [email protected].
D.M., Professor, Head of the Department of Skin and Venereal Diseases

194044, Russian Federation, St. Petersburg, ul. Academician Lebedeva, 6

Bibliography

  1. Coates L. C., Murphy R., Helliwell P. S. NEW GRAPPA RECOMMENDATIONS FOR THE MANAGEMENT OF PSORIASIS AND PSORIATIC Arthritis: Process, Challenges and Implementation. Br j Dermatol. 2016; 174 (6): 1174-1178.
  2. Warren R. B., Smith R. L., Campalani E., Eyre S., Smith C. H., Barker J. N. et al. GENETIC VARIATION IN EFFLUX TRANSPORTS INFLUENES OUTOME TO METHOTREXATE THORAPY IN PATIENTS WITH PSORIASIS. J Invest Dermatol. 2008; 128 (8): 1925-1929.
  3. Villanova F., Di Meglio P., Nestle F. O. Biomarkers in psoriasis and psoriatic arthritis. Ann Rheum Dis. 2013; 72: 104-110.
  4. ARNOLD T., Schaarschmidt M.L., HERR R. ET AL. Drug Survival Rates and ReaSons for Drug Discontinuation in Psoriasis. J dtsch dermatol ges. 2016; 14 (11): 1089-1099.
  5. Heath M. S., Kolli S. S., Dowling J. R., CLINE A., Feldman S. R. Pharmacotheraputic Strategies for Standard Treatment-Resistant Psoriasis. Expert Opin Pharmacother. 2018; 27: 1-12.
  6. Sevimoglu T., TURANLI B., BEREKETOGLU C., ARGA K. Y., Karadag A. S. Systems Biomarkers in Psoriasis: Integrative Evaluation of Computational and Experimental Data At Transcript and Protein Levels. Gene. 2018; 20; 647: 157-163.
  7. MAYEUX R. Biomarkers: Potential Uses and Limitations. Neurorx. 2004; 1 (2): 182-188.
  8. FDA-NIH Biomarker Working Group. Best (Biomarkers, EndPoints, And Other Tools) Resource. Silver Spring (MD): Food and Drug Administration (US), 2016. https://www.ncbi.nlm.nih.gov/books/nbk326791/
  9. Guitart J. R. JR, Johnson J. L., Chien W. W. Research Techniques Made Simple: The Application of Crispr-Cas9 and Genome Editing in Investigative Dermatology. J Invest Dermatol. 2016; 136 (9): E87-E93.
  10. RUBEIS G., STEGER F. A BURDEN FROM BIRTH? Non-Invasive Prenatal Testing and The Stigmatization of People with Disability. BioEthics. 2019; 33 (1): 91-97.
  11. Hyrutdinov V. R. Genetic passport of patient with psoriasis. Herald of dermatology and venereology. 2011; 4: 14-19.
  12. Prinz J. C. Human Leukocyte Antigen-Class I ALLELES AND THE AUTOREACTIVE T CELL RESPONSE IN PSORIASIS PATHOGENESIS. Front Immunol. 2018; 30; 9: 954.
  13. Kolbinger F., Loesche C., Valentin M. A. et al. β-Defensin 2 IS A Responsive Biomarker of IL-17A-Driven Skin Pathology in Patients with Psoriasis. J Allergy Clin Immunol. 2017; 139 (3): 923-932.
  14. Glazewska E. K., Niczyporuk M., Lawicki S. et al. Roc Analysis of Selected Matrix Metalloproteinases (MMPS) And Tissue Inhibitors of Metalloproteinases (TIMPS) in PSORIATIC PATIENTS. Postepy Dermatol Alergol. 2018; 35 (2): 167-173.
  15. D'Erme A. M., Wilsmann-Theis D., Wagenpfeil J. et al. IL-36γ (IL-1F9) IS A BIOMARKER FOR PSORIASIS Skin Lesions. J Invest Dermatol. 2015; 135 (4): 1025-1032.
  16. Paskin A. Yu., Zhukov A. S., Khairutdinov V. R., Belousova I. E., Samtsov A. V., Garabajiu A.V. Study of the level of expression of interleukin-36γ in the skin of patients with a gloaching psoriasis. Herald of dermatology and venereology. 2019; 95 (4): 25-33.
  17. Krasavin M. Yu., Gureev M. A., Garabadzhiu A.V. and others.Ингибирование нейтрофильной эластазы и катепсина G как новый подход к лечению псориаза: oт фундаментальной биологии к разработке мишень-специфичных препаратов. Доклады Академии наук. 2019;487(4):455–459.
  18. Frasca L., Palazzo R., Chimenti M. S. et al. Anti-LL37 antibodies are present in psoriatic arthritis (PsA) patients: new biomarkers in PsA. Front Immunol. 2018;12;(9):1936.
  19. Хайрутдинов В. Р., Жуков А. С., Пономарев И. А. и др. Роль полиморфных генов программируемой клеточной гибели в формировании риска развития псориаза. Herald of dermatology and venereology. 2009;4:4–9.
  20. Onsun N., Pirmit S., Ozkaya D. et al. The HLA-Cw12 Allele Is an Important Susceptibility Allele for Psoriasis and Is Associated with Resistant Psoriasis in the Turkish Population. Scientific World Journal. 2019;25:784–792.
  21. Mahendran S. M., Chandran V. Exploring the Psoriatic Arthritis Proteome in Search of Novel Biomarkers. Proteomes. 2018;6(1).
  22. Zhu T., Jin H., Shu D. et al. Association of IL36RN mutations with clinical features, therapeutic response to acitretin, and frequency of recurrence in patients with generalized pustular psoriasis. Eur J Dermatol. 2018;28(2):217–224.
  23. Solberg S. M., Sandvik L. F., Eidsheim M. et al. Serum cytokine measurements and biological therapy of psoriasis — Prospects for personalized treatment? Scand J Immunol. 2018;11:e12725.
  24. Campalani E., Arenas M., Marinaki A. M. et al. Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis. J Invest Dermatol. 2007;127(8):1860–1867.
  25. Indhumathi S., Rajappa M., Chandrashekar L. et al. Pharmacogenetic markers to predict the clinical response to methotrexate in south Indian Tamil patients with psoriasis. Eur J Clin Pharmacol. 2017;73(8):965–971.
  26. Kuang Y. H., Lu Y., Yan K. X. et al. Genetic polymorphism predicting Methotrexate efficacy in Chinese patients with psoriasis vulgaris. J Dermatol Sci. 2019;93(1):8–13.
  27. Vasilopoulos Y., Sarri C., Zafiriou E. A pharmacogenetic study of ABCB1 polymorphisms and cyclosporine treatment response in patients with psoriasis in the Greek population. Pharmacogenomics J. 2014;14(6):523–525.
  28. Young H. S., Summers A. M., Read I. R. et al. Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis. J Invest Dermatol. 2006;126:453–459.
  29. Ovejero-Benito M. C., Prieto-Pérez R., Llamas-Velasco M. et al. Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis. Pharmacogenomics. 2018;19(1):7–16.
  30. Ovejero-Benito M. C., Muñoz-Aceituno E., Reolid A. et al. Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis. Am J Clin Dermatol. 2018;19(2):209–222.
  31. Wilkinson N., Tsakok T., Dand N. et al. Defining the therapeutic range for adalimumab and predicting response in psoriasis: a multicentre prospective observational cohort study. J Invest Dermatol 2019;139:115–123.
  32. Masouri S., Stefanaki I., Ntritsos G. et al. A pharmacogenetic study of psoriasis risk variants in a Greek population and prediction of responses to anti-TNF-a and anti-IL-12/23 agents. Mol Diagn Ther. 2016;20:221–225.
  33. Prieto-Pérez R., Llamas-Velasco M., Cabaleiro T. et al. Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis. Pharmacogenomics. 2017;18:157–164.
  34. Loft N. D., Skov L., Iversen L. et al. Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis. Pharmacogenomics J. 2017. http://www.nature.com/doifinder/10.1038/tpj.2017.31
  35. Talamonti M., Botti E., Galluzzo M. et al. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predis-poses to clinical response to interleukin 12/23 blocker ustekinumab. Br j Dermatol. 2013;169:458–463.
  36. Talamonti M., Galluzzo M., Chimenti S., Costanzo A. HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up. J Am Acad Dermatol. 2016;74:374–375.
  37. Talamonti M., Galluzzo M., van den Reek J.M. et al. Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients. Br j Dermatol. 2017.
  38. Dand N., Duckworth M., Baudry D. et al. BADBIR Study Group; BSTOP Study Group; PSORT Consortium. HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. J Allergy Clin Immunol.2019;143(6):2120–2130.
  39. Garbaraviciene J., Diehl S., Varwig D. et al. Platelet P-selectin reflects a state of cutaneous inflammation: possible application to monitor treatment efficacy in psoriasis. Experimental Dermatology. 2010;19(8):736–741.
  40. Hong X., Jiang S., Marmolejo N. et al. Serum vascular endothelial growth factor receptor 3 as a potential biomarker in psoriasis. Exp Dermatol. 2018;27(9):1053–1057.
  41. Polat M., Bugdayci G., Kaya H., Oğuzman H. Evaluation of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in Turkish patients with chronic plaque psoriasis. Acta Dermatovenerol Alp Pannonica Adriat. 2017;26(4):97–100.
  42. Khandpur S., Gupta V., Das D., Sharma A. Is there a correlation of serum and tissue T helper-1 and -2 cytokine profiles with psoriasis activity and severity? A cross-sectional study. Indian J Dermatol Venereol Leprol. 2018;84(4):414–418.
  43. Sutherland A., Power R. J., Rahman P., O'Rielly D. D. Pharmacogenetics and pharmacogenomics in psoriasis treatment: current challenges and future prospects. Expert Opin Drug Metab Toxicol. 2016;12(8):923–935.
  44. Hsu L., Armstrong A. W. Anti-drug antibodies in psoriasis: a critical evaluation of clinical significance and impact on treatment response. Expert Review of Clinical Immunology. 2013;(10):949–958.
  45. Liau M. M., Oon H. H. Therapeutic drug monitoring of biologics in psoriasis. Biologics. 2019;5(13):127–132.
  46. Mahil S. K., McSweeney S. M., Kloczko E. et al. Does weight loss reduce the severity and incidence of psoriasis or psoriatic arthritis? A Critically Appraised Topic. Br J Dermatol. 2019;6. doi:10.1111/bjd.17741
  47. Artemyeva A. V., Chernyaeva E. V., Zhukov A. S., Platonova A. V., Khairutdinov V. R., Samtsov A. V. Results of treatment of patients with plaque psoriasis with psoriatic onychodystrophy with BCD-085. Phase II analysis of a clinical trial. Experimental and clinical pharmacology. 2019;82(6):39–44.
  48. Dopytalska K., Sobolewski P., Błaszczak A. et al. Psoriasis in special localizations. Reumatology. 2018;56(6):392–398.
  49. Passos A. N., de A Rêgo V. R. P., Duarte G. V. et al. Facial involvement and the severity of psoriasis. Int J Dermatol. 2019;58(11):1300–1304.
  50. Fitzpatrick's J. Dermatology in General Medicine. 8th ed. 2 volume set. McGraw-Hill Education – Europe, 2012. 3076 p.
  51. Mourad A., Straube S., Armijo-Olivo S., Gniadecki R. Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2019;181(3):450–458.
  52. Heath M. S., Kolli S. S., Dowling J. R. et al. Pharmacotherapeutic strategies for standard treatment-resistant psoriasis. Expert Opin Pharmacother. 2019;20(4):443–454.

© Zhukov A.S., Khairutdinov V.R., Samtsov A.V., 2019

This article is licensed under the Creative Commons Attribution 4.0 International License.